8-K: Scorpius Holdings Secures $12 Million in Convertible Note Financing
Private Placement Announcement
Scorpius Holdings has entered into a securities purchase agreement for a $12 million private placement of senior secured convertible notes and warrants.
Summary
- Scorpius Holdings has secured a $12.05 million private placement through a securities purchase agreement.
- The financing includes the issuance of senior secured convertible notes with an aggregate principal amount of $13,388,889, reflecting a 10% original issue discount.
- The company will also issue warrants to purchase up to 13,388,889 shares of common stock.
- Net proceeds to the company are estimated at $3.3 million after accounting for the repurchase of pre-funded warrants and repayment of a promissory note.
- The notes bear interest at 9% per annum, payable quarterly in cash, with a potential increase to 15% upon an event of default.
- The notes are convertible into common stock at a price of $0.50 per share, subject to certain adjustments and limitations.
- The warrants are exercisable at $0.50 per share and expire five years from the issuance date.
- The company has agreed to maintain a net monthly cash burn of not more than $1.8 million, decreasing by $500,000 every three months.
- The company is required to file a registration statement for the resale of the shares within 30 days and to use its best efforts to have it declared effective within 75 days (or 135 days if reviewed by the SEC).
Sentiment
Score: 5
Explanation: The financing provides necessary capital, but the terms are not particularly favorable, with a high default interest rate and a cash burn limit. The sentiment is neutral to slightly negative.
Positives
- The financing provides Scorpius Holdings with a significant capital infusion.
- The convertible notes offer a potential future equity upside for investors.
- The warrants provide additional potential for equity participation.
- The company has a defined plan to reduce its cash burn over time.
Negatives
- The notes have a 10% original issue discount, reducing the immediate cash received by the company.
- The notes have a high default interest rate of 15%.
- The company is subject to a net monthly cash burn limit.
- The company is restricted from incurring new indebtedness, subject to limited exceptions.
Risks
- The company's ability to meet the cash burn targets may impact its operations.
- Failure to obtain stockholder approval for the issuance of shares could trigger cash payments to note holders.
- The company's ability to maintain its listing on the NYSE American is critical.
- The company is subject to various events of default, including the departure of the CEO.
- The company is restricted from entering into variable rate transactions for 12 months.
Future Outlook
The company anticipates receiving approximately $3.3 million in net proceeds from the offering, which will be used for general corporate purposes. The company is also required to file a registration statement for the resale of the shares within 30 days and to use its best efforts to have it declared effective within 75 days (or 135 days if reviewed by the SEC).
Industry Context
This financing is a common method for small-cap companies to raise capital, particularly those in the biotechnology sector. The use of convertible notes and warrants is a typical structure for such financings, offering investors both debt and equity participation.
Comparison to Industry Standards
- The 10% original issue discount is within the typical range for convertible note financings of this type.
- The 9% interest rate is relatively standard for secured debt, but the increase to 15% upon default is a significant risk factor.
- The $0.50 conversion and exercise price is a common structure for companies with low share prices.
- The requirement to maintain a net monthly cash burn is a common covenant in financings of this type, designed to ensure the company's financial stability.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares upon conversion of the notes and exercise of the warrants.
- Employees may be affected by the company's efforts to reduce its cash burn.
- Creditors may be impacted by the company's restrictions on incurring new debt.
Next Steps
- The company will file a registration statement for the resale of the shares.
- The company will hold a stockholder meeting to approve the issuance of shares.
- The company will work to maintain its listing on the NYSE American.
Key Dates
| Date | Description |
|---|---|
| December 5, 2024 | Date of the Securities Purchase Agreement. |
| December 6, 2024 | Expected Closing Date of the private placement. |
| January 2, 2025 | First Interest Payment Date. |
| March 31, 2025 | Deadline for the first Stockholder Meeting to obtain Stockholder Approval. |
| July 1, 2025 | Deadline for the second Stockholder Meeting to obtain Stockholder Approval. |
Keywords
convertible notes, warrants, private placement, financing, senior secured, common stock, cash burn, registration statement, securities purchase agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.